Harvard Bioscience
HBIO
87 hedge funds and large institutions have $144M invested in Harvard Bioscience in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 32 reducing their positions, and 9 closing their positions.
100% more call options, than puts
Call options by funds: $10K | Put options by funds: $5K
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
30% more capital invested
Capital invested by funds: $111M → $144M (+$33.3M)
7% more funds holding
Funds holding: 81 → 87 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 6.63% → 6.63% (-0%)
16% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.32M |
| 2 |
RA
Royce & Associates
New York
|
+$1.23M |
| 3 |
Renaissance Technologies
New York
|
+$1.03M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$1.01M |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
+$973K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.51M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.23M |
| 3 |
DGHMC
Dalton, Greiner, Hartman, Maher & Co
New York
|
-$728K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$649K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$373K |
HBIO Hedge Fund Activity: Q1 2021 in Review
87 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2021, worth a combined $144M — up 30% from $111M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new HBIO positions and 9 closed out — a net gain of 6 holders — while 27 added to existing stakes and 32 trimmed.
The largest buyer was Portolan Capital Management, adding an estimated $1.32M. The largest seller was Vanguard Group, cutting an estimated $1.51M.
- 87 institutional investors held Harvard Bioscience (HBIO) as of Q1 2021, up from 81 in Q4 2020.
- Funds reported $144M of Harvard Bioscience stock for Q1 2021, up 30% quarter-over-quarter.
- 15 funds opened new Harvard Bioscience positions in Q1 2021 and 9 closed out, a net change of +6 holders.
- The largest Harvard Bioscience buyer in Q1 2021 was Portolan Capital Management, an estimated $1.32M added.
- The largest Harvard Bioscience seller in Q1 2021 was Vanguard Group, an estimated $1.51M sold.
Based on aggregated 13F filings for Q1 2021.